Results 1 to 10 of about 20,715 (114)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway [PDF]

Frontiers in Immunology, 2019
Both neutralization and antibody-dependent cellular cytotoxicity (ADCC) may be required for effective protection against HIV-1 infection. While there is extensive information on the targets of early neutralizing antibody (nAb) responses, much less is ...
Dieter Mielke, Gama Bandawe, Justin Pollara, Melissa-Rose Abrahams, Tinashe Nyanhete, Penny L. Moore, Penny L. Moore, Penny L. Moore, Penny L. Moore, Ruwayhida Thebus, Nicole L. Yates, John C. Kappes, John C. Kappes, Christina Ochsenbauer, Nigel Garrett, Nigel Garrett, Salim Abdool Karim, Salim Abdool Karim, Georgia D. Tomaras, David Montefiori, Lynn Morris, Lynn Morris, Lynn Morris, Lynn Morris, Guido Ferrari, Carolyn Williamson, Carolyn Williamson, Carolyn Williamson   +27 more
doaj   +2 more sources

Evaluating Fc-mediated antibody functions against SARS-CoV-2 in PLHIV: reduced FcγRIIIa-dependent activity and ADCC despite preserved neutralising antibodies [PDF]

Frontiers in Immunology
BackgroundAntibody-dependent cellular cytotoxicity (ADCC) is a critical Fc-mediated immune mechanism contributing to antiviral defence. However, its functionality in people living with HIV (PLHIV) following SARS-CoV-2 exposure remains poorly understood ...
Swarali Kurle, Pratiksha Pansambal, Madhuri Thakar, Manisha Ghate, Shubhangi Bichare, Pallavi Shidhaye, Sumit Aggarwal   +6 more
doaj   +2 more sources

How past transient viremia shape natural killer cells’ antibody-dependent functions in youth with perinatal HIV [PDF]

iScience
Summary: Despite effective antiretroviral therapy, people living with HIV (PLWH) may experience transient viremia episodes, which may impact Natural Killer (NK) cell antibody-dependent cellular cytotoxicity (ADCC).
Arianna Rotili, Chiara Pighi, Alessandro Pucci, Alessia Neri, Giuseppe Rubens Pascucci, Nicole Colantoni, Stefania Bernardi, Elena Morrocchi, Federica Betto, Silvia Di Cesare, Donato Amodio, Mathias Lichterfeld, Nicola Cotugno, Paolo Palma   +13 more
doaj   +2 more sources

NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers [PDF]

BMC Cancer
Objective This study aimed to develop a high-affinity therapeutic antagonist to overcome tumor-produced MUC16/CA125 (herein CA125) mediated immunosuppression of anticancer therapeutic antibodies and antibody–drug conjugates (ADCs).
Nicholas C. Nicolaides, James Bradford Kline, Luigi Grasso   +2 more
doaj   +2 more sources

Natural Killer Cell Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity Against Plasmodium falciparum-Infected Red Blood Cells. [PDF]

Methods Mol Biol, 2022
Dick JK, Hart GT.
europepmc   +2 more sources

Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide [PDF]

Clinical & Translational Immunology
Objectives The anti‐PD‐L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD‐1/L1 immune checkpoint, while inducing antibody‐dependent cellular cytotoxicity (ADCC) from CD16a+ NK cells.
Lachlan J Dobson, Barry D Hock, Ariana HT Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan   +6 more
doaj   +2 more sources

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies

eLife, 2021
A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity
Laura E Doepker, Sonja Danon, Elias Harkins, Duncan K Ralph, Zak Yaffe, Meghan E Garrett, Amrit Dhar, Cassia Wagner, Megan M Stumpf, Dana Arenz, James A Williams, Walter Jaoko, Kishor Mandaliya, Kelly K Lee, Frederick A Matsen IV, Julie M Overbaugh   +15 more
doaj   +1 more source

A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line

STAR Protocols, 2023
Summary: Current protocols measure antibody-dependent cellular cytotoxicity (ADCC) in vitro using peripheral blood mononuclear cells (PBMCs), but isolation and variability among donors limit the viability and reproducibility of this approach.
Roos Vincken, Ana Ruiz-Saenz
doaj   +1 more source

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Frontiers in Immunology, 2020
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM).
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang, Wilfried Passe-Coutrin, Alain Fournier, Yu-Tzu Tai, Kenneth C. Anderson, Dmitri Wiederschain, Keith Bahjat, Francisco J. Adrián, Marielle Chiron   +17 more
doaj   +1 more source

High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. [PDF]

PLoS ONE, 2013
The role of Antibody-dependent cellular cytotoxicity (ADCC) responses in HIV-1 controllers is still unclear due to the heterogeneity of these patients.
Olivier Lambotte, Justin Pollara, Faroudy Boufassa, Christiane Moog, Alain Venet, Barton F Haynes, Jean-François Delfraissy, Asier Saez-Cirion, Guido Ferrari   +8 more
doaj   +1 more source